IMCR — Immunocore Holdings plc

—
Nasdaq · Health Care · Biotechnology · CIK 1671927 ·
Last close
$27.81
Market Cap
$1.43B
52W High
$40.72
52W Low
$27.31
ADV30
512,568
Next earnings
2026-11-06

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 102,222,000 101,546,000 -13,609,000 -14,222,000 1,129,239,000 512,245,000 709,533,000
Jun 2026 115,927,000 114,839,000 -2,996,000 -808,000 1,119,422,000 484,920,000 699,624,000
Mar 2026 106,677,000 106,243,000 7,280,000 12,971,000 1,072,095,000 452,675,000 678,422,000
Dec 2025 104,478,000 101,775,000 -19,691,000 -30,060,000 1,067,269,000 467,709,000 686,236,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-34,958,000
Investing CF
$7,805,000
Financing CF
$23,291,000
CapEx
$-6,195,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.37
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-819,112,000
Inventory
$7,791,000
Receivables
$95,350,000
ST Investments
$395,291,000
EBIT TTM
$9,969,000
Pretax Income TTM
$-2,732,000
Interest Exp TTM
$12,701,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$430,775,008
EBITDA
$756,000
Free Cash Flow
$35,592,124
Enterprise Value
$1,150,690,176
Total Cash
$880,211,008
Total Debt
$434,959,008
Shares Out
51,498,617
Trailing EPS
$-0.64
Book Value
$7.52
ROE
-4.5%
ROA
-0.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 400,016,000 -45,353,000 -35,514,000 1,067,269,000 686,236,000 381,033,000 -10,712,000
Dec 2024 310,202,000 -70,461,000 -51,087,000 1,009,506,000 648,790,000 360,716,000 26,061,000
Dec 2023 249,428,000 -59,649,000 -55,287,000 597,001,000 228,158,000 368,843,000 2,940,000
Dec 2022 174,361,000 -51,708,000 -52,543,000 526,762,000 187,859,000 338,903,000 -49,209,000

TTM Snapshot

Revenues TTM
$430,775,000
NetIncome TTM
$-18,074,000
OpCashFlow TTM
—
Assets (Latest)
$1,119,422,000
Forward EPS
$-0.99

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $20.00 · spot: $27.51 · call volume: 1,080 · put volume: 2
Expected Move to 2027-04-16: ±$8.55 (31.08%) — implied range $18.96 – $36.06 · ATM straddle on $30.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MEOBF MESOBLAST LTD $1.48B $1.14 —
MESO MESOBLAST LTD $1.55B $11.91 —
ALVO Alvotech $1.56B $4.37 —
NVAX NOVAVAX INC $1.31B $7.96 —
TSHA Taysha Gene Therapies, Inc. $1.30B $4.00 —

News headlines (Yahoo Finance, 1h cache)

Immunocore to present at upcoming investor conferences
2026-11-09 12:00 · Yahoo
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
2026-11-06 17:00 · Yahoo
Immunocore reports third quarter financial results and provides a business update
2026-11-06 14:00 · Yahoo
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
2026-10-29 13:00 · Yahoo
Should First Type 1 Diabetes Dosing Require Action From Immunocore Stock Investors?
2026-10-29 00:14 · Yahoo
GeneDx Holdings And 2 Other Top Healthcare Stocks
2026-10-17 15:11 · Yahoo
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
2026-10-15 11:00 · Yahoo
Top 3 Healthcare Stocks To Watch In October 2026
2026-10-10 14:17 · Yahoo
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
2026-09-15 15:22 · Yahoo
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
2026-09-14 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.